Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AbbVie Inc (NYSE:ABBV)

60.96
Delayed Data
As of 4:02pm ET
 -0.19 / -0.31%
Today’s Change
51.60
Today|||52-Week Range
68.12
-2.65%
Year-to-Date
AbbVie Increases Price of Humira
3:25pm / GuruFocus News - Paid Partner Content
Vertex Pharma (VRTX) Q4 Earnings: Stock Likely to Beat?
Jan 19 / Zacks.com - Paid Partner Content
Can Q4 Earnings Revitalize Healthcare ETFs?
11:40am / Zacks.com - Paid Partner Content
Bristol-Myers (BMY) Q4 Earnings: Will the Stock Disappoint?
Jan 19 / Zacks.com - Paid Partner Content
Here Is Why to Grab These 3 Top-Quality Marijuana Stocks in 2017
11:19am / TheStreet.com - Paid Partner Content
Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?
Jan 19 / Zacks.com - Paid Partner Content
10 Questions That Need to Be Asked Ahead of Johnson & Johnson's Q4 Report
8:40am / MotleyFool.com - Paid Partner Content
How Johnson & Johnson Beat Every Other Big Pharma Stock in 2016
Jan 19 / MotleyFool.com - Paid Partner Content
AbbVie Gets FDA Approval for Lymphoma Drug
Jan 22 / GuruFocus News - Paid Partner Content
Allergan's Uterine Fibroids Candidate Positive in Phase III
Jan 18 / Zacks.com - Paid Partner Content
3 Incredibly Cheap High-Yield Dividend Stocks
Jan 22 / MotleyFool.com - Paid Partner Content
5 Most Important Drugs to Johnson & Johnson in 2017
Jan 18 / MotleyFool.com - Paid Partner Content
What's in Store for Abbott Labs (ABT) This Earnings Season?
Jan 20 / Zacks.com - Paid Partner Content
What???s Ahead for Johnson & Johnson (JNJ) in Q4 Earnings?
Jan 18 / Zacks.com - Paid Partner Content
Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?
Jan 20 / Zacks.com - Paid Partner Content
Biotech Sector to See M&A, Earnings Action
Jan 17 / TheStreet.com - Paid Partner Content
4 Drug Stocks Poised to Surprise this Earnings Season
Jan 20 / Zacks.com - Paid Partner Content
Coherus Offers Positive Phase III Data on Humira Biosimilar
Jan 13 / Zacks.com - Paid Partner Content
Celgene (CELG) Q4 Earnings: Will the Stock Pull a Surprise?
Jan 20 / Zacks.com - Paid Partner Content
Trump Attacks Biotech & Pharma: ETFs Bleed
Jan 12 / Zacks.com - Paid Partner Content
Abbvie (ABBV) Imbruvica Approved in Lymphoma Indication
Jan 20 / Zacks.com - Paid Partner Content
7 Reasons AbbVie's Stock Could Soar in 2017
Jan 12 / MotleyFool.com - Paid Partner Content
Are You Undervaluing These 3 Biopharmas' Pipelines?
Jan 20 / MotleyFool.com - Paid Partner Content
Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short
Jan 11 / Zacks.com - Paid Partner Content
4 Best Marijuana Stocks to Play the Green Rush
Jan 19 / Zacks.com - Paid Partner Content
AbbVie's HCV Combo Favorable in Japanese Phase III Study
Jan 10 / Zacks.com - Paid Partner Content
Boehringer Ingelheim's Humira Biosimilar Under Review by EMA, FDA
Jan 19 / GuruFocus News - Paid Partner Content
Pfizer's Humira Biosimilar Meets Primary Endpoint in Study (Revised)
Jan 09 / Zacks.com - Paid Partner Content
McKesson (MCK) Q3 Earnings: Stock Likely to Disappoint?
Jan 19 / Zacks.com - Paid Partner Content